Background and Aims Although the progression of papillary thyroid microcarcinoma (PTMC) is relatively slow, cervical lymph node metastasis is still present. The previous study suggested that the BRAF^V600E mutation and the abnormal expressions of relevant proteins of the Wnt/β-catenin signaling pathway may be associated with the occurrence and development and cervical lymph node metastasis of PTMC. Therefore, this study was conducted to investigate further the BRAF^V600E mutation and the expressions of β-catenin and cyclin D1 in the clinically node-negative (cN0) PTMC tissue and the significance.Methods The surgical specimens and clinicopathologic data of 120 patients with confirmed cN0 PTMC from March 2018 to September 2021 were collected. The BRAFV600E mutation and expression levels of β-catenin and cyclin D1 in the tissue samples were determined by immunohistochemical staining, and their relations with the clinicopathologic characteristics of patients were analyzed.Results The favorable expression rates of BRAFV600E mutant protein, β-catenin, and cyclin D1 in PTMC tissue were significantly higher than those in tumor-adjacent tissue (70% vs. 31.7%, 35.8% vs. 20.8%, 57.5% vs. 34.2%, all P<0.05). Positive expression of cyclin D1 protein was significantly related to tumor diameter, positive expression of BRAFV600E mutant protein was significantly associated with the number of lesions, and positive expressions of BRAFV600E mutant protein, β-catenin, and cyclin D1 were all mainly related to central lymph node metastasis (all P<0.05).Conclusion BRAFV600E mutation, β-catenin, and cyclin D1 expressions are significantly enhanced in cN0 PTMC tissue. Their expressions may be the essential reason for the progression and central lymph node metastasis of PTMC.